AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Leucine zipper putative tumor suppressor 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9Y250

UPID:

LZTS1_HUMAN

Alternative names:

F37/esophageal cancer-related gene-coding leucine-zipper motif; Fez1

Alternative UPACC:

Q9Y250; D3DSQ6; Q9Y5V7; Q9Y5V8; Q9Y5V9; Q9Y5W0; Q9Y5W1; Q9Y5W2

Background:

Leucine zipper putative tumor suppressor 1 (LZTS1), also known as Fez1, plays a crucial role in cell growth regulation. It is believed to stabilize the CDC2-cyclin B1 complex, contributing to cell cycle regulation and preventing uncontrolled cell proliferation. This protein's involvement in such fundamental cellular processes underscores its potential as a key player in tumor suppression.

Therapeutic significance:

Given its association with esophageal cancer, understanding the role of Leucine zipper putative tumor suppressor 1 could open doors to potential therapeutic strategies. Its function in stabilizing cell cycle complexes suggests that targeting LZTS1 pathways may offer new avenues for cancer treatment, particularly in combating esophageal malignancies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.